EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia

Totsapol Jirasomprasert, Li-Yuan Tian, Dian-Ping You, Ya-Kun Wang, Lei Dong, Ya-Hui Zhang, Guo-Xiang Hao, John van den Anker, Yue-E Wu, Bo-Hao Tang, Wei Zhao, Yi Zheng

Pediatric Drugs · 2025

DOI: 10.1007/s40272-024-00664-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Drugs, 2025. Verfasst von Totsapol Jirasomprasert und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory …. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Piperacillin, Pneumonia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Taishan Scholar Program of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: We aimed to determine the piperacillin disposition and optimize the dosing regimens for infants and children with pneumonia. METHODS: An opportunistic sampling strategy was used in this pharmacokinetic study. High-performance liquid chromatography was used to measure the concentrations of piperacillin in plasma samples. A population pharmacokinetic model was conducted using NONMEM. RESULTS: The pharmacokinetic data of 90 samples from 64 infants and children with pneumonia (age range: 0.09-1.72 years for infants and 2.12-11.10 years for children) were available. A two-compartment model with first-order elimination was the most suitable model to describe the population pharmacokinetics of piperacillin. A covariate analysis indicated that body weight and age were significant factors affecting clearance. Monte Carlo simulations showed that a 50-mg/kg every 8 h or every 12 h dosing regimen results in underdosing. Results both in infants and children showed that an extended infusion (3 h) of various dosing regimens (80, 100, or 130 mg/kg) three times daily or a 300-mg/kg continuous infusion can reach a therapeutic level based on the chosen target for the probability of target attainment threshold of 70%, 80%, and 90% at minimum inhibitory concentration breakpoints of 8 mg/L and 16 mg/L. CONCLUSIONS: A population pharmacokinetic model was obtained to evaluate the disposition of piperacillin, and the optimal dosing regimens were provided for use in infants and children with pneumonia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPiperacillinPneumoniaHumansInfantChild, PreschoolMaleFemaleChildMonte Carlo MethodModels, BiologicalDose-Response Relationship, DrugMicrobial Sensitivity Tests

Substanzen

Anti-Bacterial AgentsPiperacillin

Autor:innen und Institutionen

  • Department of Clinical Pharmacy, Institute of Clinical Pharmacology, Key Laboratory of Chemical Biology (Ministry of Education), NMPA Key Laboratory for Clinical Research and Evaluation of Innovative Drug, School of Pha…
  • Department of Respiratory Care, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
  • Pediatric Research Institute, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
  • Department of Pharmacy, Children's Hospital of Hebei Province affiliated to Hebei Medical University, Shijiazhuang, China.
  • Department of Pharmacy, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Taishan Scholar Program of Shandong Province

Zitieren

APA

Jirasomprasert, T., Tian, L. Y., You, D. P., Wang, Y. K., Dong, L., Zhang, Y. H., Hao, G. X., van den Anker, J., Wu, Y. E., Tang, B. H., Zhao, W., & Zheng, Y. (2025). Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia. Pediatric Drugs. https://doi.org/10.1007/s40272-024-00664-4

Vancouver

Jirasomprasert T, Tian LY, You DP, Wang YK, Dong L, Zhang YH, et al. Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia. Pediatric Drugs. 2025. doi:10.1007/s40272-024-00664-4

BibTeX
@article{Jirasomprasert2025,
  author = {Jirasomprasert, Totsapol and Tian, Li-Yuan and You, Dian-Ping and Wang, Ya-Kun and Dong, Lei and Zhang, Ya-Hui and Hao, Guo-Xiang and van den Anker, John and Wu, Yue-E and Tang, Bo-Hao and Zhao, Wei and Zheng, Yi},
  title = {Population Pharmacokinetics and Dose Optimization of Piperacillin in Infants and Children with Pneumonia},
  journal = {Pediatric Drugs},
  year = {2025},
  doi = {10.1007/s40272-024-00664-4}
}
Kostenlos starten →